EPO Patents = 1

Forward Citations = 6

Loading Chart...

4 inventors (with patents filed for the assignee):

Gustav Gaudernack (4 out of 21 patents)

Else Marit Inderberg Suso (3 out of 4 patents)

Anne-Marie Rasmussen (3 out of 4 patents)

4. Audun Tornes (1 out of 2 patents)

4 patents: Sort by Forward Citations

1. 11529403 - Telomerase polypeptide vaccine for treating cancer (2022-12-20),

2. 11419927 - Vaccine in combination with an immune checkpoint inhibitor for use in treating cancer (2022-08-23),

3. 10383928 - Telomerase polypeptide vaccine for treating cancer (2019-08-20),

4. 9657068 - Telomerase polypeptide vaccine for treating cancer (2017-05-23),

Ultimovacs is a clinical-stage pharmaceutical company developing novel immunotherapies for the treatment of cancer. Their lead product candidate, UV1, is a therapeutic cancer vaccine designed to induce a specific T cell response against tumors. Ultimovacs' mission is to improve the lives of cancer patients by harnessing the power of the immune system to fight cancer.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

4 Patents

#120 in Oslo

#392 in Norway

Oslo, Norway

Ultimovacs as

Forward Citations = 6

4 inventors:

Gustav Gaudernack (4 out of 21 patents)

Else Marit Inderberg Suso (3 out of 4 patents)

Anne-Marie Rasmussen (3 out of 4 patents)

4. Audun Tornes (1 out of 2 patents)

Please report any incorrect information to support@idiyas.com

1 patent (EPO):

Please report any incorrect information to support@idiyas.com